111(YI) - 2024 Q1 - Quarterly Report

Introduction and Highlights This section provides an overview of 111, Inc.'s financial performance for the fourth quarter and full fiscal year 2023, highlighting key revenue and profitability metrics Fourth Quarter 2023 Highlights 111, Inc. reported a 1.0% year-over-year decrease in Q4 2023 net revenues to RMB4.1 billion, with gross segment profit declining and operating losses increasing Q4 2023 Financial Highlights | Metric | Q4 2023 (RMB) | Q4 2023 (US$) | YoY Change | Q4 2022 (RMB) | | :-------------------------------- | :------------ | :------------ | :--------- | :------------ | | Net Revenues | 4.1 billion | 578.7 million | -1.0% | 4.15 billion | | Gross Segment Profit | 214.3 million | 30.2 million | -15.5% | - | | Total Operating Expenses | 420.8 million | 59.3 million | +16.3% | 361.9 million | | Loss from Operations | 206.5 million | 29.1 million | +90.5% | 108.4 million | | Non-GAAP Loss from Operations | 55.2 million | 7.8 million | +39.0% | 39.7 million | - Total operating expenses, excluding share-based compensation, decreased as a percentage of net revenues to 6.6% from 7.1% in Q4 2022. The quarter included RMB153 million in unrecognized share-based compensation upon cancellation of a subsidiary's share option plan and RMB17 million in severance expenses from organizational optimization[2] Fiscal Year 2023 Highlights For the full fiscal year 2023, 111, Inc. achieved a 10.6% year-over-year increase in net revenues to RMB14.9 billion, improving operational efficiency and reducing operating losses FY 2023 Financial Highlights | Metric | FY 2023 (RMB) | FY 2023 (US$) | YoY Change | FY 2022 (RMB) | | :-------------------------------- | :------------ | :------------ | :--------- | :------------ | | Net Revenues | 14.9 billion | 2.1 billion | +10.6% | 13.5 billion | | Gross Segment Profit | 849.0 million | 119.6 million | +1.1% | - | | Total Operating Expenses | 1.20 billion | 168.89 million | -0.8% | 1.21 billion | | Loss from Operations | 350.1 million | 49.3 million | -5.6% | 371.0 million | | Non-GAAP Loss from Operations | 123.9 million | 17.5 million | -42.0% | 213.6 million | | Cash & Cash Equivalents, Restricted Cash, Short-term Investments | 673.7 million | 94.9 million | -27.0% | 922.7 million | - Total operating expenses, excluding share-based compensation, decreased as a percentage of net revenues to 6.5% in FY 2023 from 7.8% in FY 2022[4] Management Commentary and Strategic Outlook Management discussed Q4 revenue adjustments and full-year growth, emphasizing improved operational efficiency and outlining future strategic investments for performance and market leadership Management Commentary and Strategic Outlook Management discussed Q4 revenue adjustments and full-year growth, emphasizing improved operational efficiency and outlining future strategic investments for performance and market leadership - Q4 2023 net revenues saw a slight adjustment, decreasing by 1.0% year-over-year, attributed to a strong comparable quarter in 2022 benefiting from COVID-related activities[6] - Full year 2023 net revenues grew by 10.6%, and gross segment profit increased by 1.1%[6] - Operational efficiency improved in 2023 through advancements in digitization, management processes, pricing strategies (PIS Intelligent Pricing System), and supply chain streamlining (Smart Supply Chain innovations)[6] - Future strategies include strategic investments in operational efficiency, product diversification, enhanced partner ecosystems, organizational optimization, self-owned brand development, and unwavering commitment to digitization[7] Detailed Fourth Quarter 2023 Financial Results This section provides a detailed breakdown of 111, Inc.'s financial performance for the fourth quarter of 2023, covering revenues, costs, and profitability Net Revenues and Segment Profit (B2B & B2C) In Q4 2023, total net revenues decreased by 1.0% to RMB4.11 billion, with B2B revenue flat and B2C revenue experiencing a significant decline Q4 2023 B2B Net Revenue and Segment Profit (in thousands RMB) | Metric | Q4 2022 | Q4 2023 | YoY Change | | :------------------ | :------ | :------ | :--------- | | B2B Product Revenue | 3,999,066 | 3,996,772 | -0.1% | | B2B Service Revenue | 22,808 | 24,045 | 5.4% | | B2B Sub-Total | 4,021,874 | 4,020,817 | 0.0% | | B2B Segment Profit | 226,877 | 198,949 | -12.3% | | B2B Segment Profit % | 5.6% | 4.9% | - | Q4 2023 B2C Net Revenue and Segment Profit (in thousands RMB) | Metric | Q4 2022 | Q4 2023 | YoY Change | | :------------------ | :------ | :------ | :--------- | | B2C Product Revenue | 119,354 | 85,578 | -28.3% | | B2C Service Revenue | 7,019 | 2,231 | -68.2% | | B2C Sub-Total | 126,373 | 87,809 | -30.5% | | B2C Segment Profit | 26,615 | 15,305 | -42.5% | | B2C Segment Profit % | 21.1% | 17.4% | - | Operating Costs and Expenses Total operating costs and expenses in Q4 2023 increased by 1.4% year-over-year to RMB4.32 billion, driven by increases in selling, general, and technology expenses Q4 2023 Operating Costs and Expenses (in millions RMB) | Expense Category | Q4 2022 (RMB) | Q4 2023 (RMB) | YoY Change | | :-------------------------- | :------------ | :------------ | :--------- | | Cost of Products Sold | 3,894.75 | 3,894.37 | -0.01% | | Fulfillment Expenses | 118.8 | 101.3 | -14.7% | | Selling and Marketing Expenses | 134.1 | 173.5 | +29.4% | | General and Administrative Expenses | 73.0 | 98.0 | +34.2% | | Technology Expenses | 37.2 | 49.1 | +31.9% | - Excluding share-based compensation, selling and marketing expenses as a percentage of net revenues decreased to 2.6% from 2.7% in Q4 2022[13] - General and administrative expenses as a percentage of net revenues remained at 0.9%, and technology expenses remained at 0.6%[14] Profitability (GAAP & Non-GAAP) In Q4 2023, both GAAP and Non-GAAP loss from operations, net loss, and net loss attributable to ordinary shareholders worsened year-over-year Q4 2023 Profitability (in millions RMB) | Metric | Q4 2022 (RMB) | Q4 2023 (RMB) | Q4 2023 (% of Net Rev) | Q4 2022 (% of Net Rev) | | :--------------------------------------- | :------------ | :------------ | :--------------------- | :--------------------- | | Loss from Operations | 108.4 | 206.5 | 5.0% | 2.6% | | Non-GAAP Loss from Operations | 39.7 | 55.2 | 1.3% | 1.0% | | Net Loss | 104.1 | 205.2 | 5.0% | 2.5% | | Non-GAAP Net Loss | 35.4 | 53.9 | 1.3% | 0.9% | | Net Loss Attributable to Ordinary Shareholders | 114.4 | 210.4 | 5.1% | 2.8% | | Non-GAAP Net Loss Attributable to Ordinary Shareholders | 45.7 | 59.0 | 1.4% | 1.1% | Detailed Fiscal Year 2023 Financial Results This section provides a detailed breakdown of 111, Inc.'s financial performance for the full fiscal year 2023, covering revenues, costs, and profitability Net Revenues and Segment Profit (B2B & B2C) For FY 2023, total net revenues increased by 10.6% to RMB14.9 billion, driven by B2B growth while B2C net revenue declined FY 2023 B2B Net Revenue and Segment Profit (in thousands RMB) | Metric | FY 2022 | FY 2023 | YoY Change | | :------------------ | :------ | :------ | :--------- | | B2B Product Revenue | 12,995,131 | 14,483,935 | 11.5% | | B2B Service Revenue | 80,039 | 86,831 | 8.5% | | B2B Sub-Total | 13,075,170 | 14,570,766 | 11.4% | | B2B Segment Profit | 743,513 | 769,594 | 3.5% | | B2B Segment Profit % | 5.7% | 5.3% | - | FY 2023 B2C Net Revenue and Segment Profit (in thousands RMB) | Metric | FY 2022 | FY 2023 | YoY Change | | :------------------ | :------ | :------ | :--------- | | B2C Product Revenue | 408,305 | 357,975 | -12.3% | | B2C Service Revenue | 33,223 | 19,388 | -41.6% | | B2C Sub-Total | 441,528 | 377,363 | -14.5% | | B2C Segment Profit | 96,463 | 79,384 | -17.7% | | B2C Segment Profit % | 21.8% | 21.0% | - | Operating Costs and Expenses Total operating costs and expenses for FY 2023 increased by 10.2% to RMB15.3 billion, with improved sales efficiency noted despite some expense increases FY 2023 Operating Costs and Expenses (in millions RMB) | Expense Category | FY 2022 (RMB) | FY 2023 (RMB) | YoY Change | | :-------------------------- | :------------ | :------------ | :--------- | | Cost of Products Sold | 12,676.7 | 14,099.2 | +11.2% | | Fulfillment Expenses | 401.4 | 400.5 | -0.2% | | Selling and Marketing Expenses | 457.9 | 448.4 | -2.1% | | General and Administrative Expenses | 205.6 | 224.2 | +9.0% | | Technology Expenses | 139.5 | 124.3 | -10.9% | - Excluding share-based compensation, selling and marketing expenses as a percentage of net revenues decreased to 2.5% from 3.0% in FY 2022[20] - General and administrative expenses as a percentage of net revenues decreased to 0.7% from 0.9%, and technology expenses decreased to 0.6% from 0.9%[22] Profitability (GAAP & Non-GAAP) For FY 2023, GAAP loss from operations decreased by 5.6% to RMB350.1 million, and Non-GAAP loss significantly improved by 42.0% FY 2023 Profitability (in millions RMB) | Metric | FY 2022 (RMB) | FY 2023 (RMB) | FY 2023 (% of Net Rev) | FY 2022 (% of Net Rev) | | :--------------------------------------- | :------------ | :------------ | :--------------------- | :--------------------- | | Loss from Operations | 371.0 | 350.1 | 2.3% | 2.7% | | Non-GAAP Loss from Operations | 213.6 | 123.9 | 0.8% | 1.6% | | Net Loss | 376.1 | 353.4 | 2.4% | 2.8% | | Non-GAAP Net Loss | 218.7 | 127.3 | 0.9% | 1.6% | | Net Loss Attributable to Ordinary Shareholders | 416.9 | 392.7 | 2.6% | 3.1% | | Non-GAAP Net Loss Attributable to Ordinary Shareholders | 259.5 | 166.5 | 1.1% | 1.9% | Financial Position and Liquidity This section reviews the company's financial position, including cash and investments, and addresses redeemable non-controlling interests Cash and Investments As of December 31, 2023, cash and cash equivalents, restricted cash, and short-term investments totaled RMB673.7 million, a 27.0% decrease from 2022 Cash and Investments (in millions RMB) | Metric | Dec 31, 2022 | Dec 31, 2023 | YoY Change | | :---------------------------------------------------- | :----------- | :----------- | :--------- | | Cash and cash equivalents, restricted cash, and short-term investments | 922.7 | 673.7 | -27.0% | Redeemable Non-Controlling Interests The company has RMB1.1 billion outstanding to 1 Pharmacy Technology investors, with RMB0.2 billion in redemption requests received and ongoing negotiations for repayment - Total outstanding amount owed to investors of 1 Pharmacy Technology is RMB1.1 billion[24] - Redemption requests totaling RMB0.2 billion have been received from certain investors[24] - The company is negotiating with investors and stakeholders regarding repayment and/or restructuring of redemption obligations[24] Supplementary Information This section provides additional context, including conference call details, the use of non-GAAP measures, exchange rate information, and forward-looking statements Conference Call 111, Inc. hosted an earnings conference call on March 21, 2024, to discuss its Q4 and FY 2023 unaudited financial results, with registration and replay details provided - Earnings conference call held on Thursday, March 21, 2024, at 7:30 AM U.S. Eastern Time[26] - Participants were required to register online to receive dial-in numbers, a Direct Event passcode, and a unique Registration ID[26] - A telephone replay was available until March 28, 2024, and a live and archived webcast was accessible on the company's website[27] Use of Non-GAAP Financial Measures The company uses non-GAAP financial measures, excluding share-based compensation, to assess core operating performance and facilitate comparisons, acknowledging their limitations - Non-GAAP measures include loss from operations, net loss, net loss attributable to ordinary shareholders, and loss per ADS, all excluding share-based compensation expenses (net of tax where applicable)[27] - Rationale for using non-GAAP measures is to identify underlying business trends undistorted by non-cash, variable share-based compensation expenses, providing a reasonable basis for measuring core operating performance and comparison with peers[29] - Limitations include not reflecting all income and expense items affecting operations and potential incomparability with non-GAAP information from other companies[30] Exchange Rate Information Statement The report provides translations of RMB amounts into U.S. dollars for convenience, using an exchange rate of RMB7.0999 to US$1.00 as of December 29, 2023 - All translations from RMB to U.S. dollars in the announcement are made at a rate of RMB7.0999 to US$1.00[32] - The exchange rate is based on the H.10 statistical release of the Board of Governors of the Federal Reserve System as of December 29, 2023[32] Forward-Looking Statements This press release contains forward-looking statements based on current expectations, which involve inherent risks and uncertainties that could cause actual results to differ materially - Forward-looking statements are identified by terminology such as 'will,' 'expects,' 'anticipates,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'target,' 'confident' and similar statements[33] - Potential risks and uncertainties include compliance with evolving regulatory requirements, effective competition, managing business growth, achieving profitability, controlling risks in pharmaceutical retail/wholesale, and maintaining Nasdaq listing standards[33] - The company does not undertake any obligation to update forward-looking statements as a result of new information, future events, or otherwise, except as required under applicable law[35] About 111, Inc. This section provides an overview of 111, Inc., detailing its role as a leading tech-enabled healthcare platform in China and its key services About 111, Inc. 111, Inc. is a leading tech-enabled healthcare platform in China, connecting patients with medicine and healthcare services digitally through various platforms - 111, Inc. is a leading tech-enabled healthcare platform company in China, digitally connecting patients with medicine and healthcare services[36] - Key services include: 1 Pharmacy (online retail pharmacy), offline virtual pharmacy network, 1 Clinic (internet hospital for online consultation, e-prescription, patient management), and 1 Medicine (B2B platform for pharmacies)[36] - The company also offers an omni-channel drug commercialization platform to strategic partners, including digital marketing, patient education, data analytics, and pricing monitoring[36] Unaudited Condensed Consolidated Financial Statements This section presents the unaudited condensed consolidated financial statements, including balance sheets, statements of comprehensive loss, and cash flows Balance Sheets The unaudited condensed consolidated balance sheets show a decrease in total assets from RMB3.47 billion in 2022 to RMB3.09 billion in 2023, with an increased shareholders' deficit Unaudited Condensed Consolidated Balance Sheets (in thousands RMB) | Metric | Dec 31, 2022 | Dec 31, 2023 | | :-------------------------------- | :----------- | :----------- | | Total Current Assets | 3,235,825 | 2,933,331 | | Total Assets | 3,473,814 | 3,089,036 | | Total Current Liabilities | 2,725,110 | 2,774,437 | | Total Liabilities | 2,825,579 | 2,842,306 | | Redeemable Non-Controlling Interests | 1,056,939 | 841,451 | | Total Shareholders' Deficit | (414,599) | (583,451) | Statements of Comprehensive Loss The unaudited condensed consolidated statements of comprehensive loss show a net loss of RMB205.2 million for Q4 2023 and RMB353.4 million for FY 2023, with varying operational loss trends Unaudited Condensed Consolidated Statements of Comprehensive Loss (in thousands RMB) | Metric | Q4 2022 | Q4 2023 | FY 2022 | FY 2023 | | :-------------------------------- | :------ | :------ | :------ | :------ | | Net Revenues | 4,148,247 | 4,108,626 | 13,516,698 | 14,948,129 | | Loss from Operations | (108,427) | (206,538) | (371,001) | (350,097) | | Net Loss | (104,076) | (205,221) | (376,069) | (353,433) | | Net Loss Attributable to Ordinary Shareholders | (114,431) | (210,366) | (416,878) | (392,693) | | Loss per ADS: Basic and Diluted | (1.38) | (2.48) | (5.00) | (4.66) | Statements of Cash Flows For FY 2023, the company reported net cash used in operating activities of RMB447.2 million, a significant increase from the prior year, alongside positive investing and financing cash flows Unaudited Condensed Consolidated Statements of Cash Flows (in thousands RMB) | Activity | FY 2022 | FY 2023 | | :-------------------------------- | :------ | :------ | | Net cash provided by (used in) operating activities | (23,152) | (447,244) | | Net cash (used in) provided by investing activities | (47,173) | 151,743 | | Net cash provided by financing activities | 22,735 | 205,978 | | Net decrease in cash and cash equivalents, and restricted cash | (43,881) | (93,243) | | Cash and cash equivalents, and restricted cash at the end of the period | 716,791 | 623,548 | Reconciliation of GAAP and Non-GAAP Results This section details the reconciliation of GAAP to non-GAAP financial results, primarily by adjusting for share-based compensation expenses to show core performance Unaudited Reconciliation of GAAP and Non-GAAP Results (in thousands RMB) | Metric | Q4 2022 (GAAP) | Q4 2023 (GAAP) | Q4 2023 (Non-GAAP) | FY 2022 (GAAP) | FY 2023 (GAAP) | FY 2023 (Non-GAAP) | | :--------------------------------------- | :------------- | :------------- | :----------------- | :------------- | :------------- | :----------------- | | Loss from Operations | (108,427) | (206,538) | (55,186) | (371,001) | (350,097) | (123,927) | | Net Loss | (104,076) | (205,221) | (53,869) | (376,069) | (353,433) | (127,263) | | Net Loss Attributable to Ordinary Shareholders | (114,431) | (210,366) | (59,014) | (416,878) | (392,693) | (166,523) | | Loss per ADS | (1.38) | (2.48) | (0.70) | (5.00) | (4.66) | (1.98) | - Share-based compensation expenses added back for reconciliation were RMB151.4 million in Q4 2023 and RMB226.2 million for FY 2023[49]